^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FRS2 mutation

    i
    Other names: FRS2, Fibroblast Growth Factor Receptor Substrate 2, Suc1-Associated Neurotrophic Factor Target 1, FGFR-Signaling Adaptor SNT, FGFR Substrate, SNT-1, Epididymis Secretory Sperm Binding Protein, FGFR Signalling Adaptor, FRS2alpha, FRS1A, FRS2A, SNT1, SNT
    Entrez ID:
    10818
    Related biomarkers:
    CNA
    3years
    Targeted genomic analysis of 364 adrenocortical carcinomas. (PubMed, Endocr Relat Cancer)
    As more than half of ACC have one or more potentially actionable genomic alterations, this highlights the value of targeted sequencing for this orphan cancer with a poor prognosis. In addition, significant incidence of MMR gene alterations suggests that immunotherapy is a promising therapeutic for a considerable subset of ACC patients.
    Journal • IO biomarker
    |
    LRP1B (LDL Receptor Related Protein 1B) • IL7R (Interleukin 7 Receptor) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2)
    |
    LRP1B mutation • FRS2 mutation